• CLLS

Earnings call: Cellectis reports robust cash reserves, new R&D initiatives

Cellectis reported increased cash reserves and strategic collaborations with AstraZeneca, focusing on new therapies while deprioritizing UCART123, aiming for a stable financial outlook until 2027.